TEPKINLY® (epcoritamab) Receives Second European Commission Approval for … – Business Wire
TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or …Read More
The Heartbeat of World events
TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or …Read More
